These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1558566)

  • 1. Vaccination with gp160 in HIV.
    Seligman SJ
    N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1558566
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccination with gp160 in HIV.
    Oyaizu N; Chirmule N; Pahwa S
    N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccination with gp160 in HIV.
    Stanberry LR; Bernstein DI; Myers MG
    N Engl J Med; 1992 Jan; 326(5):347-8. PubMed ID: 1728748
    [No Abstract]   [Full Text] [Related]  

  • 4. [AIDS--HIV envelope protein improves vaccination response].
    GURTLER L
    Fortschr Med; 1991 Dec; 109(35):10-1. PubMed ID: 1774002
    [No Abstract]   [Full Text] [Related]  

  • 5. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 6. AIDS vaccine boosts immunity in HIV patients.
    RN; 1991 Oct; 54(10):103. PubMed ID: 1925340
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV-1 soluble antigens induced CD8+ cytotoxic T-cell responses in an immunized individual.
    Achour A; Moukrim Z; Picard O; Bizzini B; Burny A; Zagury D
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):395-400. PubMed ID: 7580833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.
    Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
    Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157
    [No Abstract]   [Full Text] [Related]  

  • 9. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
    DePalma L
    Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
    [No Abstract]   [Full Text] [Related]  

  • 11. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current progress in HIV vaccines.
    Westblom TU; Belshe RB; Gorse GJ
    Mo Med; 1991 Nov; 88(11):762-5. PubMed ID: 1805131
    [No Abstract]   [Full Text] [Related]  

  • 13. Positive response. Encouraging results in the search for an AIDS vaccine.
    Beardsley T
    Sci Am; 1991 Aug; 265(2):26. PubMed ID: 1862329
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
    Bergmann C; Stohlmann SA; McMillan M
    Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human trials of AIDS vaccines: current status and future directions.
    Koff WC; Fauci AS
    AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684
    [No Abstract]   [Full Text] [Related]  

  • 17. Cellular immune response to HIV gp160 vaccine.
    Stricker RB; Goldberg B
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):989. PubMed ID: 7914236
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gp160 of commercial HIV western blots is not gp160env. Should criteria for seropositivity be revised?
    Fenouillet E; Blanes N; Gluckman JC
    AIDS; 1991 Jun; 5(6):770. PubMed ID: 1883550
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
    Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
    N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.